The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by Maspin

Cancer Research

Volumn 60, Issue 17, 2000, Pages 4771-4778

  McGowen, R ^a   Biliran H , Jr ^a   Sager, R ^a   Sheng, S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MASPIN; PLASMINOGEN; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL SURFACE; COMPETITIVE INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION;

ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL MEMBRANE; CELL MOVEMENT; GENES, TUMOR SUPPRESSOR; HUMANS; KINETICS; MALE; PLASMIN; PROSTATIC NEOPLASMS; PROTEINS; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SERPINS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034282726     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Maspin a serpin with tumor-suppressing activity in human mammary epithelial cells
2. RNA genetics of breast cancer: Maspin as a paradigm
3. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene
4. Revertant DCIS in human axillary breast carcinoma metastasis
5. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells
6. Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor
7. Maspin a tumor suppressing serpin
8. γ-Linolenic acid regulates expression of maspin and the motility of cancer cells
9. Production, purification and characterization of recombinant maspin proteins
10. Maspin suppresses the invasive phenotype of human breast carcinoma
11. Maspin is an angiogenesis inhibitor
12. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin
13. The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin
14. Maspin plays an important role in mammary gland development
15. Immunoassays
16. Evaluation of the MTT and SRB assays for resting LAK cell-mediated growth inhibition of various adherent and non-adherent tumor target cells
17. Comparative intravital and postmortem studies on chemically induced blood-brain barrier damage tested with trypan blue
18. Electrophoretic analysis of plasminogen activators in polyacrylamide gel containing sodium dodecyl sulfate and copolymerized substrates
19. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
20. Preparation and characterization of latent α1-antitrypsin
21. Autocrine saturation of pro-urokinase receptors on human A431 cells
22. Inhibition of receptorbound urokinase by plasminogen activator inhibitors
23. Cloning and expression of the receptor for human urokinase plasminogen activator a central molecule in cell surface
24. Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors
25. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
26. Two distinct urokinase-serpin interactions regulate the initiation of cell surface-associated plasminogen activation
27. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation
28. The role of conformational changes in serpin structure and function
29. Function of maspin
30. Heat-induced conversion of ovalbumin into a proteinase inhibitor
31. The suicide substrate reaction between plasminogen activator inhibitor-1 and thrombin is regulated by the cofactors vitronectin and heparin
32. Kinetic analysis of integrin-dependent cell adhesion on vitronectin - The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides
33. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix associated vitronectin
34. Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and the reactive-center loop peptide
35. Three-state unfolding and self-association of maspin, a tumor-suppressing serpin
36. Cellular receptors for the plasminogen activators
37. Characterization of the binding of different conformational forms of plasminogen activator inhibitory-1 to vitronectin. Implications for the regulation of pericellalar proteolysis
38. LDL-receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation
39. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen activator inhibitory type 1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor
40. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines
41. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen
42. 1H nuclear magnetic resonance
43. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator
44. Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal beparin binding domain of fibronectin
45. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer
46. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in nodenegative breast cancer: A prospective study on multicenter basis
47. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer
48. Absence of host plasminogen activator inhibitor I. prevents cancer invasion and vascularization